According to Lambert et al. [82], GLP-1 has been shown to improve insulin sensitivity and reduce hepatic glucose production in the animal model of NAFLD, which inhibits the development of liver steatosis, NASH, and liver fibrosis. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.